Key takeaways
- Pregabalin can relieve certain types of nerve pain, but substantial relief is not universal and results differ by condition. Cochrane review.
- The European Lyrica authorisation includes adult nerve pain, generalised anxiety disorder and use alongside other treatment for certain seizures. EMA Lyrica overview.
- Dizziness and sleepiness can make an otherwise helpful treatment difficult to live with. Kidney function also affects prescribing. EMA Lyrica information.
- Severe breathing problems have been reported, sometimes without opioids. Other sedating medicines and respiratory disease can increase risk. MHRA respiratory warning.
- Physical dependence is not the same as addiction. Either risk deserves an honest discussion and a supported stopping plan. MHRA January 2026 update.
Pain may be less intrusive on pregabalin, yet the next morning can feel slower or unsteady. That is a real treatment trade-off, not evidence that the medicine is either wonderful or worthless. The question is whether it improves the parts of daily life that matter enough to justify its drawbacks.
Lyrica is a brand of pregabalin. A review should focus on the condition being treated, the response so far and the complete medicine list, rather than on the brand name alone.
What kind of pain is pregabalin most likely to help?
The review supports benefit for some people with pain after shingles or painful diabetic neuropathy.
The Cochrane review included 45 trials and 11,906 participants, followed for 2 to 16 weeks. Most had pain after shingles, painful diabetic neuropathy or mixed neuropathic pain. Neuropathic pain comes from damage or disease in the sensory nervous system; a burning or electric sensation alone cannot establish that diagnosis. Review methods.
A large Cochrane review found benefit for some people with painful diabetic neuropathy and pain after shingles, while evidence was limited or less convincing for several other conditions. Many participants did not achieve substantial relief. That is a reason to agree a review point and meaningful goals, rather than assume a repeat prescription must continue indefinitely. Cochrane review.
| At a treatment review | What is worth comparing |
|---|---|
| Pain | Fewer difficult episodes, not only a lower score |
| Function | Walking, work or ordinary tasks that have become easier |
| Tolerability | Daytime sleepiness, balance, swelling or weight change |
| Overall value | Whether the improvement matters more than the drawbacks |
This is a conversation aid, not a test that decides treatment by itself.
Why is the same medicine also used for anxiety?
Pregabalin has evidence and an overseas authorisation for generalised anxiety disorder, but that does not make it a treatment for every kind of anxiety.
Pregabalin binds to a part of calcium channels involved in nerve signalling. Its precise therapeutic mechanism is not fully understood. The European authorisation includes generalised anxiety disorder in adults; that is separate from deciding where it belongs in an individual’s treatment plan. EMA overview.
The EMA overview describes eight generalised-anxiety studies in more than 3,000 patients, assessed after four to eight weeks. Anxiety scores improved by at least 50% in 52% taking Lyrica, compared with 38% taking placebo. Those findings concern generalised anxiety disorder. Diagnosis, prior treatment and adverse effects still determine the individual plan. EMA anxiety results.
For depression and cognitive symptoms, see the separate vortioxetine article.
Which side effects can change the decision?
Dizziness and sleepiness each affect more than 1 in 10 patients in the EMA summary; breathing risk also needs review.
Pregabalin is cleared through the kidneys. Impaired kidney function can require a different prescription, so mention kidney disease when discussing dizziness or sleepiness, as well as the other medicines you take. EMA information.
The UK regulator has reported severe respiratory depression both with and without opioids. Risk is higher with other medicines that suppress the central nervous system, impaired breathing or kidney function, and in older adults. Alcohol can add to sedation. Slow or shallow breathing, unusual difficulty waking or blue lips requires emergency help. Do not drive while sleepy or impaired. MHRA safety advice.
Does needing a gradual reduction mean addiction?
No. Physical dependence can develop during prescribed treatment without compulsive medicine use.
The MHRA’s 8 January 2026 update distinguishes the body adapting to a medicine from craving and difficulty controlling its use. Physical dependence can cause withdrawal after stopping or reducing treatment. Addiction can involve seeking more despite harm, early repeat requests or using a medicine for reasons other than its intended purpose. The update calls for clearer warnings in leaflets and on packs, and non-judgmental conversations with patients. MHRA update.
Do not stop abruptly or copy another person’s taper. In the MHRA advice, intolerable withdrawal is a reason for the prescriber to consider pausing the reduction or returning to the previous stage. A taper can take weeks or months. If more than one medicine with withdrawal risks is involved, the plan should say which is reduced first.
Our low-dose naltrexone evidence review covers a separate pain-treatment question. Interest in that medicine does not establish it as a substitute for pregabalin.
Do and don’t
Do:
- Record changes in walking, work and ordinary tasks alongside the pain score.
- Mention opioids, sleeping tablets, alcohol and kidney problems at each review.
Don’t:
- Increase treatment yourself when it seems less effective; ask about the response and possible tolerance.
- Interpret physical dependence as a personal failing.
